Verve Therapeutics (VERV)
(Delayed Data from NSDQ)
$4.67 USD
+0.07 (1.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.66 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Verve Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -200.07 | -157.39 | -120.31 | -45.70 | -19.30 |
Depreciation/Amortization & Depletion | -8.93 | 1.78 | 3.04 | 1.71 | 0.03 |
Net Change from Assets/Liabilities | 17.70 | 8.38 | -2.91 | 2.64 | 2.66 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 41.74 | 24.90 | 42.30 | 6.09 | 9.16 |
Net Cash From Operating Activities | -149.55 | -122.33 | -77.88 | -35.27 | -7.44 |
Property & Equipment | -9.28 | -13.23 | -4.36 | -3.42 | -1.86 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 36.97 | -142.72 | -234.74 | -47.70 | -10.90 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 27.69 | -155.96 | -239.10 | -51.13 | -12.76 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 213.04 | 329.74 | 380.72 | 92.63 | 18.04 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.46 | -0.78 | -3.63 | 0.00 | -0.09 |
Net Cash from Financing Activities | 212.58 | 328.96 | 377.09 | 92.63 | 17.95 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 90.72 | 50.67 | 60.11 | 6.24 | -2.25 |
Cash at Beginning of Period | 120.24 | 69.57 | 9.46 | 3.22 | 5.47 |
Cash at End of Period | 210.95 | 120.24 | 69.57 | 9.46 | 3.22 |
Diluted Net EPS | -3.12 | -2.91 | -4.48 | NA | NA |
Fiscal Year End for Verve Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -98.54 | -48.74 | -200.07 | -151.72 |
Depreciation/Amortization & Depletion | NA | -4.21 | -2.34 | -8.93 | -7.11 |
Net Change from Assets/Liabilities | NA | 1.71 | -4.04 | 17.70 | 19.92 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 23.80 | 12.03 | 41.74 | 30.03 |
Net Cash From Operating Activities | NA | -77.24 | -43.08 | -149.55 | -108.87 |
Property & Equipment | NA | -1.41 | -0.43 | -9.28 | -7.10 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -10.07 | -41.20 | 36.97 | 43.68 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -11.48 | -41.63 | 27.69 | 36.58 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 24.03 | 22.79 | 213.04 | 35.26 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | -0.05 | -0.46 | -0.07 |
Net Cash from Financing Activities | NA | 24.03 | 22.73 | 212.58 | 35.19 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -64.69 | -61.98 | 90.72 | -37.09 |
Cash at Beginning of Period | NA | 210.95 | 210.95 | 120.24 | 120.24 |
Cash at End of Period | NA | 146.26 | 148.97 | 210.95 | 83.14 |
Diluted Net EPS | NA | -0.59 | -0.59 | -0.69 | -0.72 |